

CURRICULUM VITAE

Name: Lauren Virginia Wood, M.D.

Date and Place of Birth: May 27, 1959; Cleveland, Ohio

Citizenship: United States

Marital Status: Married

Address & Telephone Numbers:

Office: Vaccine Branch, CCR, NCI
Bldg. 10 Rm. 6B04, MSC 1578
10 Center Drive
Bethesda, MD 20892-1578
Phone: 301-402-0199
FAX: 301-480-8437
Email: lw51p@nih.gov

Home: 5426 Lincoln Street
Bethesda, MD 20817-3762

Present Position:

April 2005 - Present Senior Clinical Investigator
Head, Vaccine Branch Clinical Trials Team
Vaccine Branch, Center for Cancer Research
National Cancer Institute
National Institutes of Health, Bethesda, Maryland

Education:

1984 M.D. Duke University School of Medicine
Durham, North Carolina

1980 B.A. Oberlin College, Oberlin, Ohio

Medical Postdoctoral Training:

1988 - 1991 Allergy / Immunology Fellowship
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Bethesda, Maryland

1984 - 1988 Combined Internal Medicine/Pediatrics Residency Program
Baylor College of Medicine Affiliated Hospitals
Baylor College of Medicine, Houston, Texas

Professional Experience:

1996 - April 2005	Senior Clinical Investigator Pediatric HIV Working Group, HIV & AIDS Malignancy Branch National Cancer Institute National Institutes of Health, Bethesda, Maryland
1994 - 1998	Coordinator, Clinical Research Program for HIV-Infected Adolescents Project Officer, Minority Adolescent HIV Research Project: Model for Community-Based Treatment and Prevention NCI Contracts # N01-SC-47037, N01-SC-71037
1993 - 2005	Co-Director, NCI Pediatric Outpatient Clinic
1992 - 1996	Attending Physician Pediatric HIV Working Group, Pediatric Branch National Cancer Institute National Institutes of Health, Bethesda, Maryland
1991 - 1992	Clinic Physician, NIAID/CCMD Intramural AIDS Program National Institutes of Health, Bethesda, Maryland
1990 - 1991	Clinical Associate Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health, Bethesda, Maryland
1988 - 1990	NRSA Immunology Research Fellow Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health, Bethesda, Maryland
1984 - 1988	Resident Physician Baylor College of Medicine Affiliated Hospitals Houston, Texas

Academic Appointments:

1993 - Present	Assistant Professor of Pediatrics Uniformed Services University of the Health Sciences Bethesda, Maryland
----------------	---

Board Certification:

2005	Recertification American Board of Allergy and Immunology Effective: 10/21/05 - 12/31/15	
1993	Diplomat American Board of Allergy and Immunology	Certificate #: 3732
1989	Diplomat American Board of Internal Medicine	Certificate #: 129394
1989	Diplomat American Board of Pediatrics	Certificate #: 41790

Medical Licensure:

Maryland	License #: D37712	Registration Expires: 09/30/11
District of Columbia	License #: 17532	Inactive
Virginia	License #: 0101 043652	Inactive
Texas	License #: G9016	Inactive

Awards and Honors:

2010	NCI Federal Technology Transfer Award
2009	NCI Federal Technology Transfer Award
2008	NIH Clinical Center Intramural Bench-to-Bedside Award: \$200,000 Co-Principal Investigators (Bedside): Aarthi Shenoy, M.D., Hematology Branch, NHLBI Pamela Stratton, M.D., Reproductive Biology and Medicine Branch, NICHD Co-Principal Investigators (Bench): Ligia Pinto, M.D., HPV Immunology Laboratory, SAIC-NCI Frederick Lauren V. Wood, M.D., Vaccine Branch, NCI Immunogenicity of Quadrivalent Human Papilloma Virus Vaccine (HPV Types 6, 11, 16, 18) in Recipients of Allogeneic Hematologic Stem Cell Transplantation (HSCT)
2007	2007 National Medical Association Council on Concerns of Women Physicians (CCWP) Pfizer Research Award
2005	NIH Black Scientists Association, Dr. Philip J. Browning Pioneer Award
2003	NIH Clinical Center Intramural Bench-to-Bedside Award: \$200,000 Principal Investigators: Lauren V. Wood, M.D., HAMB, NCI Chad Womack, Ph.D., VRC, NIAID Use of 5 Fluorouracil (5FU) in Combination with Antiretroviral Drugs as a Salvage Strategy to Overcome Drug Resistance in Heavily Treated HIV-Infected Pediatric Patients.
2001	Child Welfare League of America J. Burt Annin Award
2001	Public Health Service Citation Award
1996	Tenured Staff Clinician, NCI
1996	NCI Division of Clinical Sciences Recognition Award
1988 - 1990	Intramural National Research Service Award, NIAID, NIH

Major Committee and Other Professional Assignments:***Intramural***

2008 – Present	Board of Tutors, NIH Clinical Research Training Program
2008 - Present	NIH Clinical Center Title 42 Committee
2001 - Present	Center for Cancer Research SC Clinical Promotion Review Panel 2007 - Present Chair, SC Clinical Promotion Review Panel
1998 - Present	NIH & NCI Search Committees: HIV & AIDS Malignancy Branch, NCI Pediatric Oncology Branch, NCI Critical Care Medicine Department, NIH Clinical Center

	Anesthesiology Department, NIH Clinical Center
	Clinical Pathology Department, NIH Clinical Center
	Experimental Transplantation & Immunology Branch, NCI
	Neuro Oncology Branch, NCI
	Diagnostic Radiology Department, NIH Clinical Center
2006	Chief, Laboratory of Pathology, NCI
	Scientific Director for Clinical Research, CCR, NCI
	Tenure Track Investigator, Laboratory of Cellular Oncology, NCI
2007	Chief, Pediatric Oncology Branch, NCI
2009	Chief, Clinical Chemistry Service, DLM, NIH Clinical Center
1996 - Present	Board of Directors, The Children's Inn, NCI, Bethesda, MD
	2006 – 2008 Chair, Board of Directors, The Children's Inn
2005 - 2006	CCR Staff Scientist/Staff Clinician Steering Committee
2005 - 2006	NIH Assembly of Scientists Executive Council (Elected)
1999 - 2002	NCI Cancer Advisory Panel for Complementary and Alternative Medicine
1998 - 2001	NIH Clinical Center Consultation Committee
1996 - 2001	NIH Clinical Center Pediatric Care Committee

Extramural

2010 – Present	White House National HIV/AIDS Strategy Interagency Working Group, Disparities Subcommittee.
2009 - Present	Data Safety Monitoring Committee, Division of Microbiology & Infectious Diseases, NIAID Protocols: 09-0014 and 09-0090.
2006 - Present	External Advisory Committee, Center for AIDS Health Disparities Research at Meharry Medical College
2005	Expert Reviewer, DAIDS, NIAID, Leadership for HIV/AIDS Clinical Trials Networks Re-competition, October 24-25, 2005.
2002	Reviewer NICHD Pediatric AIDS Clinical Trials Group Network Site Re-competition, March 5-6, 2002.
2001 - 2005	FDA Antiviral Drugs Advisory Committee
1999	REMUNE Pediatric Advisory Panel
1999	Expert Panel, IDF Clinical Trial Protocol- IVIG Licensure Workshop
1996 - 2001	Pediatric ACTG Executive Committee

Editorial Responsibilities:**Editorial Board**

2002 - Present	Editorial Board, <i>Journal of Immune-Based Therapies and Vaccines</i>
1999 - 2002	Associate Editor, <i>Clinical and Diagnostic Laboratory Immunology</i>

Ad Hoc Reviewer

2008 – Present	<i>BMC Pediatrics</i>
	<i>Cancer</i>
	<i>Clinical Cancer Research</i>
2007 - Present	<i>Clinical Infectious Disease</i>
	<i>Future HIV Therapy</i>
2005 - Present	<i>Journal of Infectious Diseases</i>

1999 - Present *Journal of Pediatrics*
 1993 - 1996 Co-Reviewer with Philip A. Pizzo, M.D.: Pediatric AIDS Foundation,
Journal of AIDS, New England Journal of Medicine, Pediatrics

Uniformed Service:

2002 Promoted to Medical Director, Captain 0-6
 1994 Promoted to Senior Surgeon, Commander 0-5
 1992 Promoted to Surgeon, Lt Commander 0-4
 1990 - Present Commissioned Officer, Reserve Corps, U.S. Public Health Service

NCI Protocol Principal Investigator:

09-C-0024 A Phase I Study of Quadrivalent A Phase I Study of Quadrivalent Human
 Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-
 Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
03-C-0169 Psychological and Environmental Factors Associated with Medication Adherence
 in Children and Adolescents with HIV Infection
99-C-0118 A Pilot Study of Hydroxyurea in Combination with Stavudine, Didanosine and
 Efavirenz in Pediatric Patients with HIV-1 Infection
96-C-0003 A Phase I/II Study of the Protease Inhibitor Ritonavir (ABT-538) in Children with
 HIV Infection
95-C-0184 A Phase I Study of Levamisole in Children and Adolescents with Advanced
 Human Immunodeficiency Virus Infection
95-C-0183 A Pilot Study of Recombinant IL-2 in Children and Adolescents with Human
 Immunodeficiency Virus Infection
95-C-0172 Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen
 in Children with HIV-1 Infection
94-C-0035 Phase I/II Study to Evaluate the Safety, Toxicity and Preliminary Efficacy of
 Combinations of Lamivudine (3TC), Zidovudine (AZT) and Didanosine (ddI) in
 Children with HIV Infection.
92-C-0096 Phase I Study of GR109714X (2'deoxy-3'Thiacytidine or 3TC) in Children with
 HIV Infection.

Lead Associate/Medically Responsible Investigator:

10-CH-0083 Phase I Trial of Safety and Immunogenicity of GARDASIL Vaccination Post
 Stem Cell Transplantation in Patients with and without Immunosuppression.
09-C-0139 Phase I/II Trial of Vaccination with Epitope-Enhanced TARP Peptide and
 Peptide-Pulsed Dendritic Cells in the Treatment of Androgen Independent
 Prostate Cancer (D0)
03-C-0215 Pregnancy in Perinatally HIV-Infected Adolescents: Epidemiologic Descriptions,
 Pregnancy Outcomes and Risk Factors Associated with Pregnancy. Multi-site
 protocol conducted with the CDC, Atlanta, GA.

Associate Investigator:

06-C-0200 Phase I Study of the Safety and Efficacy of GC1008: A Human Anti-

	Transforming Growth Factor-beta (TGFβ) Monoclonal Antibody in Patients with Advanced Renal Cell Carcinoma or Malignant Melanoma.
<u>02-C-0052</u>	Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study.
<u>02-C-0006</u>	A Phase I Study of Tenofovir Disoproxil Fumarate (PMPA Prodrug), a Novel Nucleotide Analog Reverse Transcriptase Inhibitor in Children with HIV Infection.
<u>99-C-0134</u>	A Long-Term Observational Study of Immunologic Reconstitution in HIV-1 Infected Children who are Receiving Combination Protease Inhibitor and Reverse Transcriptase Inhibitors.
<u>97-C-0119</u>	A Phase I/II Study of 2'-b-fluoro-2'3'-dideoxyadenosine (F-ddA) in Children with HIV infection
<u>96-C-0041</u>	A Pilot Study of Cylodextrin Itraconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in Children with HIV Infection.
<u>95-C-0163</u>	A Phase I/II Study of the Protease Inhibitor Indinavir (MK-639) in Children with HIV Infection.
<u>95-C-0144</u>	A Pilot Study of the Combination of Retinoic Acid and Interferon-α for Lymphoproliferative Disorders in Children with Immunodeficiency Syndromes.
<u>94-C-0147</u>	A Phase I Study to Evaluate the Safety and Activity of KNI-272 in Children with HIV Infection.
<u>93-C-0207</u>	Pilot Study for the Treatment of Non-Hodgkin's Lymphoma In Patients with Inherited and Acquired Immunodeficiency.
<u>93-C-0192</u>	Pilot Study to Evaluate the Safety and Efficacy of the Combination of Zidovudine, Didanosine, and BI-RG-5887 (Nevirapine) in Children with Progressive HIV Disease.
<u>93-C-0070</u>	Phase I/II Assessment of Oral Rifabutin Suspension for the Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in HIV-Infected Pediatric Patients and Low CD4+ Cell Counts.
<u>93-C-0021</u>	Pilot Study of the Safety, Growth and Immunologic Effects of Recombinant Human Insulin-Like Growth Factor (rHIGF-1) and Recombinant Human Growth Hormone, Nutropin (rHGH) in Children with HIV-1 Infection.
<u>92-C-0047</u>	Phase I/II Trial of Amphotericin B Lipid Complex (ABLC) in the Treatment of Hepatosplenic Candidiasis in Children with Neoplastic Diseases.
<u>91-C-0053</u>	Phase I/II Study of Oral Clarithromycin Granules in the Treatment of Disseminated MAC Complex Infection in Pediatric Patients with AIDs.
<u>91-C-0009</u>	Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2'3'-Dideoxyinosine in Children with HIV Infection.

Sponsor-Investigator INDs:

IND# 13924: Study of quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18) in immune compromised populations.

IND# 13925 (Medically Responsible Investigator): Vaccination with TARP (T-Cell Receptor Gamma Alternate Reading Frame Protein) 27-35 and TARP 29-37-9V (L37V) Peptides.

Major Professional Interests:

- ◆ Therapeutic vaccine and immune-based therapies for cancer and HIV infection
- ◆ HPV vaccines in patients with immune suppression and at excess risk for HPV-related disease
- ◆ Dendritic cell vaccines

BIBLIOGRAPHY**Publications:**

1. Koenig SK, Fuerst TR, **Wood LV**, Woods RM, Suzich JA, Jones GM, De La Cruz VF, Davey RT, Venkatesan S, Moss B, Biddison WE, Fauci AS. Mapping the fine specificity of a cytotoxic T cell response to HIV-1 Nef protein. J. Immunol 1990;145:127-135
2. Thomas CR, **Wood LV**, Douglas JG, Stelzer KJ, Koh W, Panicker R. Common emergencies in cancer medicine: infectious and treatment-related syndromes, part I. JNMA 1994;86:765-774
3. Thomas CR, Stelzer KJ, Douglas JG, Koh W, **Wood LV**, Panicker R. Common emergencies in cancer medicine: infectious and treatment-related syndromes, part II. JNMA 1994;86:839-852
4. **Wood LV** and Masur H. The pathophysiology of HIV infection and its relationship to knee disorders. In: Scott, W. Norman (ed): The Knee, Mosby-Year Book, Chicago 1994.
5. Zurlo JJ, **Wood L**, Gaglione MM, Polis MA. Effect of splenectomy on T-lymphocyte subsets in patients infected with the human immunodeficiency virus. Clin Inf Dis 1995;20:768-71
6. Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, Rubin M, Yuen G, Mueller BU, Sloas MM, **Wood L**, Balis F, Shearer GM, Brouwers P, Goldsmith J, Pizzo PA. Lamivudine (3TC) in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch Human Immunodeficiency Virus Working Group. J Infect Dis 1996;174:16-25.
7. Mueller BU, Nelson RP, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, Balis FM, Brouwers P, Hsu A, Saulis R, Sei S, **Wood LV**, et al. A phase I/II study of the protease inhibitor ritonavir in children with HIV infection. Pediatrics 1998, 101:335-343.
8. Ludlam SE, Zeidman D, **Wood LV**, Ognibene FP. Intractable wheezing due to an obstructing tracheal neuroendocrine tumor in an adolescent with HIV infection. Respiratory Care, 1998, 43:562-565.
9. Mueller BU, Sleasman J, Nelson PR, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P, Mistry G, Winchell G, Zwierski S, Boss C, Jankelevich S, Sei S, **Wood LV**, Zeichner S, Pizzo PA. A phase I/II study of the protease inhibitor Indinavir in children with HIV infection. Pediatrics, 1998, 102:101-109.
10. **Wood LV**. Immunomodulation and immune reconstitution. In: Pizzo, P. A. & Wilfert, C. M. (eds.): Pediatric AIDS: The Challenge of HIV Infection in Infants, Children and Adolescents (3rd ed). Baltimore: Williams & Wilkins, 1998, pp. 514-42.
11. Kingma DW, Mueller BU, Frekko BS, Sorbara LR, **Wood LV**, Katz D, Raffeld M, Jaffe ES. Low-grade monoclonal Epstein-Barr virus-associated lymphoproliferative disorder of the brain presenting as human immunodeficiency virus-associated encephalopathy in a child with

- acquired immunodeficiency syndrome. Archives of Pathology and Laboratory Medicine, 1999, 123:83-87.
12. **Wood LV**. Pulmonary problems. In: Zeichner, S. & Read, J.S. (eds.): Handbook of Pediatric HIV Care. Philadelphia: Lippincott-Raven, 1999, pp. 385-402.
 13. Jankelevich S, Jacobsen R, **Wood L**, Zeichner S, Serchuck L, Boon J, Dimitrov D, Yarchoan R. HIV dynamics in children on HAART(abstract). J Human Virol, 1999;2(4).
 14. Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, Cox JH, Jarosinski P, Walsek CM, Brouwers P, Venzon DJ, Xu J, Pizzo PA, Moss RB, Robb ML, **Wood LV**. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) Immunogen in children with HIV-1 infection. J Infect Dis, 1999;180:626-40.
 15. **Wood LV**. Highly active antiretroviral therapy: progress and pitfalls. (editorial) J Pediatr, 1999;135:655-57
 16. Gonzalez CE, Samakoses R, Boler AM, Hill S, **Wood LV**. Lymphoid interstitial pneumonitis in pediatric AIDS. Natural history of the disease. Ann N Y Acad Sci, 2000;918:358-61.
 17. Gonzalez CE, Adde M, Taylor P, **Wood LV**, Magrath I. Impact of chemotherapy for AIDS-related malignancies in pediatric HIV disease. Ann N Y Acad Sci, 2000;918:362-366.
 18. Pelletier R, Peter J, Antin C, Gonzalez CE, **Wood LV**, Walsh TJ. Emergence of resistance of *Candida albicans* to clotrimazole in HIV-infected children: in vitro and clinical correlations. J Clin Microbiol, 2000;38:1563-1568
 19. Miller KD, Cameron M, **Wood LV**, Dalakas MC, Kovacs JA. Lactic acidosis, hepatic steatosis and mitochondrial myopathy associated with the use of stavudine (d4T). Annals Int Med, 2000;133:192-196
 20. Toro JR, **Wood LV**, Patel NK, Turner ML. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol, 2000;136:983-985.
 21. Chiou CC, Groll AH, Gonzalez CE, Callendar D, Venzon D, Pizzo PA, **Wood LV**, Walsh TJ. Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr Infect Dis J, 2000;19:729-734.
 22. Civitello L, Wolters P, Serchuck L, **Wood L**, Jankelevich S, Yarchoan R, Brouwers P. Long-term effect of protease inhibitors on neuropsychological function and neuroimaging in pediatric HIV disease [abstract]. Ann Neurol, 2000;48:513.
 23. Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwierski S, **Wood LV**, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J Infect Dis, 2001;183(7):1116-20.

24. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, **Wood LV**, Yarchoan R, Zuckerman J, Landay A, Mackall CL. A potential role for interleukin-7 on T-cell homeostasis. *Blood* 2001;97:2983-90.
25. Sei S, Boler AM, Nguyen GT, Stewart SK, Yang Q, Edgerly M, **Wood LV**, Brouwers P, Venzon DJ. Protective effect of CCR5 $\Delta 32$ heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection. *AIDS* 2001;15:1343-52.
26. Sei S, O'Neill DP, Stewart SK, Yang Q, Kumagai M, Boler AM, Adde MA, Zwierski SL, **Wood LV**, Venzon DJ, Magrath IT. Increased level of stromal-cell derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma. *Cancer Res* 2001;61:5028-37.
27. Robinson MR, Salit RB, Bryant-Greenwood PK, Zeichner SL, **Wood LV**, Jaffe ES, Van Waes C, Magrath I. Burkitt's/Burkitt's-like lymphoma presenting as a bacterial sinusitis in two HIV-infected children. *AIDS Patient Care and STDs* 2001;15:453-58.
28. Chiou CC, Groll AH, Mavrogiorgos N, **Wood LV**, Walsh TJ. Esophageal candidiasis in pediatric HIV-infected patients after the introduction of highly active antiretroviral therapy. *Pediatr Infect Dis J*, 2002;21:388-92.
29. Mukhopadhyay A, Wei B, Zullo SJ, **Wood LV**, Weiner H. In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors: a possible explanation for lipodystrophy syndrome. *Mitochondrion* 2002;1:511-18.
30. Patsalides AD, **Wood LV**, Atac GK, Sandifer ES, Butman JA, Patronas NJ. Cerebrovascular disease in HIV-infected pediatric patients: neuroimaging findings. *AJR Am J Roentgenol* 2002;179:999-1003.
31. Ioannidis, JPA, Contopoulos-Ioannidis, DG, Rosenberg, PS et al for the HIV Host Genetics International Meta-analysis Group. Effects of *CCR5-Δ32* and *CCR2-64I* alleles on disease progression of perinatally HIV-1 infected children: An international meta-analysis. *AIDS* 2003;17:1631-38.
32. Martin S, Wolters P, Klaas P, Perez L, and **Wood LV**: Family coping styles in families of children with HIV. *AIDS Care* 2004;16:283-92.
33. Srivastava, S, Taylor, P, **Wood, LV**, Lee, SB and Robinson, MR. Post-surgical scleritis associated with the ganciclovir implant. *Ophthalmic Surg Lasers Imaging*, 2004, 36(3):254-5.
34. Taylor, P, Worrell, C, Steinberg, SM, Hazra, R, Jankelevich, S, **Wood, LV**, Zwierski, S, Yarchoan, R and Zeichner, S. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. *Pediatrics*, 2004;114:e235-42.
35. Wiener, L., Rieckert, K., Ryder, C., **Wood, L.V.** Assessing medication adherence in adolescents with HIV when electronic monitoring is not feasible. *AIDS Pt Care STDs* 2004; 18(9):527-38.

36. **Wood LV**. Pulmonary problems. In: Zeichner, S. & Read, J.S. (eds.): Handbook of Pediatric HIV Care. (2nd ed.) Cambridge: Cambridge University Press, 2005.
37. **Wood LV**. Pulmonary problems. In: Zeichner, S. & Read, J.S. (eds.): Textbook of Pediatric HIV Care. Cambridge: Cambridge University Press, 2005, pp.479-98.
38. **Wood LV**. Antiretroviral therapy in children. In: Gendelman, H., Swindells, S., et al (eds.): Neurology of AIDS, 2nd Edition. Oxford: Oxford University Press, 2005, pp.693-710.
39. Bodaghi, S, **Wood LV**, Roby G, Ryder C, Steinberg SM, Zheng Z-M. Could human papillomaviruses be spread through blood? J Clin Micro 2005;43:5428-34.
40. Wiener LS, Battles HB and **Wood LV**. A longitudinal study of adolescents with perinatally or transfusion acquired HIV infection: sexual knowledge, risk reduction, self-efficacy and sexual behavior. AIDS & Behavior 2007;11:471-78.
41. Martin S, Elliott-DeSorbo DK, Wolters PL, Toledo-Tamula MA, Roby G, Zeichner S, **Wood LV**. Patient, caregiver and regimen characteristics associated with adherence to HAART among HIV-infected children and adolescents. Pediatric Inf Dis J 2007;26:61-67.
42. Martin S, Wolters PL, Calabrese SK, Toledo-Tamula MA, **Wood LV**, Roby G, Elliott-DeSorbo DK. The antiretroviral regimen complexity index: a novel method of quantifying regimen complexity. J AIDS 2007;45:535-44.

Abstracts:

1. Wood L, Koenig S, Wood R, Fuerst T, Newell A, Brewah A., et al. Identification of gp41 determinants recognized by antibodies in cytolytic assays. Sixth International AIDS Conference, (oral abstract Th.A.79) San Francisco, California, June 21, 1990.
2. Da Cunha A, Vitkovic L, Tyor WR, Jefferson J, Glass JD, **Wood L**, Fauci AS. Induction of transforming growth factor beta and elevated expression of Interleukin-1 in AIDS brain. Seventh International Conference on AIDS, Florence, Italy July 1991.
3. Zurlo J, **Wood L**, Mackrell M, and Polis M. Effect of splenectomy on T-lymphocyte subsets in splenectomized HIV-1 infected patients. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, (abstract no. 1480), Anaheim, CA, October 1992.
4. Lewis L, Mueller B, Sei S, Sloas M, Tudor-Williams G, Wells M, **Wood L** et al. A phase I/II study of 3TC (lamivudine) in children with HIV infection. First National Conference on Human Retroviruses and Related Infections, Washington D.C., December 1993.
5. Lewis L, Jacobsen F, Mueller B, Sandelli S, Sei S, Sloas M, Tudor-Williams G, **Wood L** et al. A phase I/II assessment of oral rifabutin suspension for the prophylaxis of *mycobacterium avium* complex (MAC) bacteremia in HIV-infected children. First National Conference on Human Retroviruses and Related Infections, Washington D.C., December 1993.

6. Lewis L, Mueller B, Shock R, Sei S, Sloas M, **Wood L**, et. al. A phase I/II study to evaluate the safety, toxicity, and preliminary efficacy of combinations of lamivudine (3TC), zidovudine (AZT), and didanosine (ddI) in children with HIV infection. The Second National Conference on Human Retroviruses and Related Infections. Washington DC; January, 1995.
7. Mueller BU, Sei S, Luzuriaga K, Anderson B, Farley M, Schwartzentruber D, Tudor-Williams G, Fox C, Sullivan J, Hirschfeld S, Lewis LL, Sloas MM, **Wood LV**, Zeichner SL, Pizzo PA. The impact of combination therapy (zidovudine + didanosine + nevirapine) on HIV-1 virus burden in peripheral blood and lymph node tissue in children. American Society of Clinical Investigation, Washington D.C., May 1995.
8. Chiou CC, Groll AH, Gonzalez CE, Callendar D, Venzon D, **Wood L**, Walsh TJ. Esophageal candidiasis in children infected with human immunodeficiency virus: clinical manifestations and risk factors. 37th Meeting of the Infectious Disease Society of America, (abstract no. 270), Arlington, VA, September 1997.
9. **Wood LV**, Wigginton J M, Zuckerman J, Higham C, Loy S, Brouwers P, Lane H C, Townley E, Jankelevich S, Serchuck L, Sei S, Zeichner S. A pilot study of recombinant IL-2 in children and adolescents with human immunodeficiency virus infection. AAAAI/AAI/CIS Joint Meeting, (oral abstract no. 433), San Francisco, CA, February 21-26, 1997.
10. **Wood LV**, Wigginton J, Zuckerman J, Washington B, Higham C, Townley E, Jankelevich S, Serchuck L, Zeichner S, Lane HC, Ficker A, Bailey L. Pharmacokinetics, tolerance and immunomodulatory activity of recombinant IL-2 in HIV-infected children and adolescents: results of a pilot study. 5th Conference on Retroviruses and Opportunistic Infections, (abstract no. 222), Chicago, IL, February 1-5, 1998.
11. Jankelevich S, Mueller B. Smith S, Boss C, Zwierski S, Steinber S, **Wood L**, Zeichner S, Serchuck L, Sleasman J, Nelson R, Nguyen B-Y, Shadle C, Pizzo P, Yarchoan R. Long-term activity of indinavir/ZDV/3TC in HIV-1-infected children: results of a phase I/II study. 5th Conference on Retroviruses and Opportunistic Infections, (abstract no. 231), Chicago, IL, February 1-5, 1998.
12. Bailey L, Nolan-Polite, E, Saunders P, Booth J, Ficker AH, Baylor MS, Holmes JJ, **Wood LV**. Barriers to enrollment of HIV-infected adolescents in clinical research protocols. Annual Meeting of the Society of Adolescent Medicine, Atlanta, GA, March 1998.
13. Walsh TJ, McEvoy M, Rishforth B, Townley E, Peter J, Roilides E, Chanock SJ, and **Wood LV**. Cyclodextrin itraconazole in the treatment of oropharyngeal candidiasis (OPC) in pediatric patients with HIV infection: a phase I/II clinical trial. Abstracts of the 38th Interscience Conference on Antimicrobial Agents Chemotherapy, (abstract no. J-145), September 1998.
14. Baylor MS, Bailey LH, Ficker AH, Nolan-Polite E, Vahovich M, Holmes JJ, **Wood LV**. Why aren't adolescents offered HIV testing? 126th Annual Meeting American Public Health Association, (session no. 2117), Washington, DC, November 17, 1998.

15. Baylor MS, Saunders P, Bailey L, Ficker A, Booth J, Nolan-Polite E, Vahovich M, Homes J, **Wood LV**. Self-disclosure of HIV status among HIV-infected adolescents. 126th Annual Meeting American Public Health Association, (session no. 2117), Washington, DC, November 17, 1998.
16. Baylor MS, Phillips JN, Eason T, Williams M, O'Brien NR, **Wood, LV**. Preliminary Analysis of type of insurance coverage and confidentiality issues regarding financial reimbursement of urban adolescent patient care. 126th Annual Meeting American Public Health Association, Washington, DC, November 18, 1998.
17. Jankelevich S, Mueller BU, Smith S, Mackall C, Zwierski S, **Wood L**, Zeichner S, Serchuck L, Sleasman J, Nelson R, Nguyen B-Y, Shadle C, Pizzo P, Yarchoan R. Regeneration of CD4+45RA+ T lymphocytes in the presence of continued viral replication in HIV-infected children treated with 96 weeks of combination indinavir, 3TC and ZDV. 6th Conference on Retroviruses and Opportunistic Infections, (abstract no. 438), Chicago, IL, January 31-February 4, 1999.
18. Gonzalez CE, Boler AM, Samakoses R, Hill S, **Wood LV**. Lymphoid interstitial pneumonitis in pediatric AIDS: natural history of the disease. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, Montreal, Canada, September 4-6, 1999.
19. Gonzalez CE, Adde M, Taylor P, **Wood LV**, Magrath I. HIV-1 RNA levels during chemotherapy for HIV-related malignancies in children with HIV infection. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, Montreal, Canada, September 4-6, 1999.
20. Groll AH, McEvoy M, Mickiene D, Piscitelli S, **Wood LV**, Walsh TJ. Cyclodextrin itraconazole suspension zur behandlung der oropharyngealen candidiasis HIV-infizierter kinder und jugendlicher. Deutschen Gesellschaft fur Kinderchirurgie, Munchen 9. Bis 12. September 1999.
21. Groll AH, Mickiene D, McEvoy M, Dad L, Townley E, Piscitelli S, **Wood L**, Walsh TJ. Pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with HIV-infection and oropharyngeal candidiasis. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, (abstract no. J-1647) San Francisco, CA, September 26-29, 1999.
22. Boler AM, Yang Q, Nguyen G, Stewart S, Edgerly M, **Wood LV**, Brouwers P, Venzon D, Sei S. Contrasting effects of CCR5 Δ32 heterozygosity on HIV-1 disease progression in HIV-1-infected children with SDF-1 wild-type vs. gene variant. 7th Conference on Retroviruses and Opportunistic Infections, (abstract no. 688), San Francisco, CA, January 30-February 2, 2000.
23. Fry TJ, Connick E, Landay A, Lederman MM, **Wood LV**, Yarchoan R, Mackall CL. A potential role for IL-7 in T-cell homeostasis in HIV-infected patients. 7th Conference on Retroviruses and Opportunistic Infections, (abstract no. LB1), San Francisco, CA, January 30- February 2, 2000.

24. Sachdev V, Ernst I, Laurienzo JM, Freidlin R, **Wood L**, Panza JA. Improved reproducibility of real-time 3-dimensional compared to conventional 2-dimensional echocardiography for the assessment of left ventricular volumes and function in children. American Society of Echocardiography, (abstract no. 364), Chicago, IL, June 14, 2000.
25. Ratto-Kim S, Robb M, Sandelli S, Williams M, Sei S, Theofan G, Diveley J, Moss RB, Venzon D, **Wood LV**. Lymphoproliferative responses induced by HIV-1 Immunogen vaccine in children with HIV infection. 38th Annual Meeting of the Infectious Diseases Society of America, (abstract no. 45), New Orleans, LA, September 7-10, 2000.
26. Polis M, Yoder C, Sidorov IA, Jankelevich S, **Wood L**, Serchuck L, Metcalf J, Boon J, Mueller BU, Gee D, Dimitrov MA, Gee E, Pizzo P, Yarchoan R, Dimitrov DS. Rate of HIV-1 decline in blood plasma during the first week on antiretroviral treatment is a major early predictor of drug efficacy. 8th Conference on Retroviruses and Opportunistic Infections, (abstract no.398) Chicago, IL, February 4-8, 2001.
27. Durier N, Steinberg S, Liewehr D, Jacobsen F, **Wood L**. Divergent surrogate marker responses that predate the HAART era: long-term clinical outcomes in HIV-infected children receiving didanosine monotherapy. 8th Conference on Retroviruses and Opportunistic Infections, (abstract no.691) Chicago, IL, February 4-8, 2001.
28. Zullo S, Wei B, Mukhopadhyay A, **Wood LV**, Weiner H. Inhibition of mitochondrial processing protease by protease inhibitors: a novel mechanism for mitochondrial dysfunction in HAART-associated lipodystrophy. 2001 NIH Research Festival, (poster V-15) Bethesda, MD, October 2-5, 2001.
29. **Wood LV**, Zuckerman J, Steinberg S, Liewehr D, DeCarlo E, Beals M, Wigginton J, The Pediatric HIV Working Group. Preliminary analysis of the safety and immunologic activity of recombinant IL-2 in children and adolescents with HIV infection. 9th Conference on Retroviruses and Opportunistic Infections (poster abstract 518-M), Seattle, WA, February 24-28, 2002.
30. Cheung HC, Iavorovska O, Zullo SJ, **Wood LV**, von Borstel RW and von Borstel RC. Mitochondrial damage in yeast induced by protease inhibitors. 33rd Annual Meeting of the Environmental Mutagen Society, (abstract 24), Anchorage, AK, April 27 – May 2, 2002. Environmental and Molecular Mutagenesis 2002 39(Suppl 33): 28.
31. **Wood LV**, Salmon JR, Hirschfeld SI, Liewehr DJ, Steinberg SM, Avila NA. Thymus imaging in pediatric HIV-infected patients receiving immune-based therapies: correlation with immunologic and virologic outcomes. Federation of Clinical Immunology Societies (FOCIS) 3rd Annual Meeting (abstract 405), Paris, France, May 15-19, 2003.
32. Martin S, Elliot, DK, Toledo-Tamula MA, Wolters PL, **Wood LV**. Comparison of knowledge and perceptions of responsibility for medication adherence between HIV-positive children and their caregivers. Society of Pediatric Psychology, Charleston, SC, April 15 – 17, 2004.

33. Calabrese S, Martin S, Elliott-DeSorbo DK, Tamula MA, Wolters P, **Wood LV**. Methodological and conceptual considerations in the assessment of antiretroviral medication adherence in HIV-positive children and adolescents. XVI International AIDS Conference, (abstract CDB0745), Toronto, Canada, August 13-16, 2006.
34. Brennan T, Martin S, Elliott-DeSorbo DK, Toledo-Tamula MA, Wolters PL, Wiener L, **Wood LV**. Social support and disclosure in HIV-positive children and adolescents: their relationship to family environment and emotional functioning. Society of Pediatric Psychology, Great Lakes Regional Conference in Child Health, Cincinnati, OH, April 26-28, 2007.
35. Walsh TJ, Shad A, Bekersky I, Gonzalez C, Groll AH, **Wood LV**, Buell D and Seibel NL. Safety, tolerability and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients. Poster Presentation, 2008 48th Annual ICAAC/IDSA 46th Annual Meeting, October 25th-28th, 2008, Washington, D.C. Abstract No.

Selected Invited Presentations:

1. Identification of gp41 Determinants Recognized by Antibodies in Cytolytic Assays. Sixth International AIDS Conference, (abstract Th.A.79), San Francisco, California, June 21, 1990.
2. HIV, Women and the Consequences in Children and Adolescents. National Association of Community Health Centers, New Orleans, Louisiana, September 1, 1993.
3. Minority Adolescent HIV Research. National Meeting on Minority Health Research and Research Training, Chicago, Illinois, March 28, 1994.
4. AZT and Pediatric AIDS. HIV/AIDS and Women: The Changing Face of AIDS Conference, Meharry Medical College, Nashville, Tennessee, September 26, 1994.
5. Current Issues in Pediatric HIV Disease: Perinatal Transmission and Adolescent Infection. CME Conference on Child Health in the '90s: Issues from Infancy to Adolescence: HIV Disease and Street Violence, The Hospital for Sick Children, Washington, D.C., September 20, 1995.
6. Adolescent HIV Infection: An Emerging Reality in the 90s. 1st Annual Maternal/Child HIV Care Conference, St. Petersburg, Florida, October 21, 1995.
7. A Pilot Study of Recombinant IL-2 in Children and Adolescents with Human Immunodeficiency Virus Infection. AAAAI/AAI/CIS Joint Meeting, (abstract no. 433), San Francisco, CA, February 22, 1997.
8. New Horizons in Treating Children with HIV Infection. National Association of Pediatric Nurse Associates and Practitioners, 18th Annual Conference, Plenary Session, Washington, DC, March 6, 1997.
9. Treatment Options for HIV/AIDS in Pediatric and Adolescent Populations. NIH CME Seminar, NE Place, Washington, DC, April 25, 1997

10. Treatment Options for Children and Adolescents with HIV Infection. Pediatric Grand Rounds, Georgetown University Medical Center, August 8, 1997.
11. Medical Aspects of Pediatric HIV/AIDS Treatment and Research. NIH CC Social Work Department Conference on Biopsychosocial Approach in Working with Persons with HIV/AIDS, Bethesda, MD, November 20, 1997.
12. Immunologic and Virologic Responses to HIV-1 Immunogen Vaccination in HIV-Infected Children: A Preliminary Analysis. University of Maryland, Institute of Human Virology Conference on Immune Reconstitution: Setting the Goal Line, Baltimore, MD, January 10, 1998.
13. Adolescent HIV Infection: Generation NeXt. NIH Rehabilitation Medicine Department Conference on Pediatric HIV: Evaluation, Medical Management and Rehabilitation, Bethesda, MD, March 19, 1998.
14. Update on Pediatric HIV Infection: Progress and Pitfalls. National Association of Pediatric Nurse Associates and Practitioners, 19th Annual Conference, Chicago, IL, March 21, 1998.
15. Treatment Options for Children and Adolescents with HIV Infection. USUHS Department of Pediatrics Grand Rounds, Bethesda, MD, April 9, 1998.
16. Barriers to Recruitment, Enrollment and Retention of Adolescents in Clinical Trials. HSC CME Conference, "A Report Card on HIV/AIDS in the Adolescent Population: Identifying Milestones and Addressing Barriers," Washington, DC, April 23, 1998.
17. Preliminary Analysis of the Safety and Immunogenicity of HIV-1 Immunogen in Children with HIV Infection. Twenty-fifth Clinical Trials Group Meeting, PACTG Vaccine Session, Washington, DC, August 3, 1998.
18. Treatment of Pediatric HIV Disease: Three Steps Forward, Two Steps Back. NIH Clinical Center Grand Rounds, Bethesda, MD, October 21, 1998.
19. Identifying Barriers to HIV Screening in Women and Adolescents. Mid-Atlantic AIDS Education & Training Center Symposium "HIV: Hard to Reach Populations--Women, Adolescents, and Children," Howard University, Washington, DC, November 24, 1998.
20. Immune-Based Therapies in Children. "HIV Vaccine Development; Global, Regional, and Thailand Update, 1999," Bangkok, Thailand, March 18, 1999.
21. Pediatric HIV Pathophysiology: Approach to Management and Treatment. Infectious Diseases Seminar, Pediatric Infectious Diseases Department, Medical College of Virginia, Richmond, VA and Division of Infectious Diseases, University of Virginia, Charlottesville, VA, June 28, 1999.
22. Immune Modulation: A New Direction for Therapy of HIV-1. International Symposium on Growth Hormone in Immune Reconstitution: Basic and Clinical Studies, St. Petersburg, FL, October 7-10, 1999.

23. Treatment of Pediatric HIV Disease. Medical College of Virginia, Department of Pediatrics Grand Rounds, Carilion Roanoke Community Hospital, Roanoke, VA, December 9, 1999
24. Reducing Perinatal HIV Transmission. Department of Pediatrics Grand Rounds, D. C. General Hospital, Washington, D.C., December 15, 1999.
25. Career Pathways in Government. National Resident Education Program, AAAAI 56th Annual Meeting, San Diego, CA, March 4, 2000.
26. Disclosing Life-Threatening Diagnosis to Minors: Who Should Decide? Clinical Center Ethics Grand Rounds, Bethesda, MD, April 5, 2000.
27. Treatment of Pediatric HIV Disease. Virginia Council of Nurse Practitioners Annual Conference, Williamsburg, VA, April 8, 2000.
28. Lymphoproliferative Responses Induced by HIV-1 Immunogen Vaccine in Children with HIV Infection. 38th Annual Meeting of the Infectious Diseases Society of America, (abstract no. 45), New Orleans, LA, September 9, 2000.
29. The Challenges of Clinical Research in the Era of Highly Active Antiretroviral Therapy. 9th Annual Conference Society of Clinical Research Associates, Arlington, VA, September 16, 2000.
30. Adolescents and AIDS: Millennium Milestones. NIH Clinical Center Medicine for the Public Lecture Series, Bethesda, MD, September 26, 2000.
31. The Epidemiology and Treatment of Pediatric and Adolescent HIV Infection: Past, Present and Future. NIH Black Scientists Association Black History Month Seminar, Bethesda, MD, February 27, 2001.
32. Government Career Pathways. National Resident Education Program, AAAAI 57th Annual Meeting, New Orleans, LA, March 17, 2001.
33. Drug Use and Risk Behaviors Among Adolescents: A Generation at Risk for HIV Infection and Other STDS. NIDA Conference on Differential Drug Use, HIV/AIDS & Related Outcomes Among Racial & Ethnic Populations, Bethesda, MD, April 26, 2001.
34. The Epidemiology and Treatment of Pediatric and Adolescent HIV Infection: Past, Present and Future. National Medical Association 2001 Annual Convention and Scientific Assembly, Nashville, TN, August 9, 2001.
35. Immune-Based Therapies in Pediatric HIV Infection. NIAID Grand Rounds, Bethesda, MD, February 22, 2002
36. Government Career Pathways. National Resident Education Program, AAAAI 58th Annual Meeting, New York, NY, March 2, 2002.
37. Health Disparities and Clinical Research: The HIV Perspective and Missed Opportunities. NIH Health Disparities Panel, 37th Annual SNMA Conference, Houston, TX, March 29,

2002.

38. AIDS Research: Where We've Been, Where We're Going, & Where We Need to Be. Plenary Speaker, AIDS Alliance for Children, Youth & Families Voices 2002 Conference, Washington, D.C., May 5, 2002.
39. Therapeutic Vaccination with HIV-1 Immunogen (REMUNE) in HIV-Infected Children & Adolescents. FASEB Therapeutic and Preventive AIDS Vaccines Conference, Tucson, AZ, July 27-August 1, 2002.
40. Keynote Plenary, Third Annual Houston Premedical Academy Research Symposium. Baylor College of Medicine, Houston, TX, January 8, 2003.
41. Government Career Pathways. National Resident Education Program, AAAAI 60th Annual Meeting, Denver, CO, March 8, 2003.
42. Keynote Plenary: 20th Century Advances and 21st Century Challenges in the Treatment of HIV Disease. Harvard Medical School 3rd Annual New England Science Symposium, February 27th, 2004, Boston, MA.
43. HIV: Barriers to Care. NIH CC Social Work Conference: Building Bridges, Health Care Disparities in Our Community, March 17th, 2004, Bethesda, MD.
44. Career Pathways in Government. National Resident Education Program, AAAAI 60th Annual Meeting, San Francisco, CA, March 20, 2004.
45. HIV & AIDS: Millennium Milestones. National Institute of Environmental Health Sciences Packard Graduate Scholars Program, Bethesda, MD, July 16th 2004.
46. Plenary Speaker: HIV Infection in Women: An Emerging Epidemic and Preventable Health Disparity. 9th International Research Centers In Minority Institutions Symposium on Health Disparities, Baltimore, MD, December 10, 2004.
47. Keynote Speaker: HIV/AIDS: Not for Gay Men Only. The Emerging Epidemic Among Women and Youth. Washington, D.C. Department of Mental Health, World AIDS Day Symposium, Washington, D.C., November 30, 2005.
48. Keynote speaker: Women of Color and the HIV Crisis: An Exploding Epidemic. Women & HIV International Clinical Conference, Dallas, TX, April 28th, 2006.
49. HIV Vaccine Development. 14th Annual Recent Advances in HIV Medicine, UT Southwestern Medical Center, Dallas, TX, October 27th, 2006.
50. Adolescent AIDS: Generation NeXt. 2006 AIDS Symposium, Medical University of South Carolina, Charleston, SC, November 17th, 2006.
51. HIV: New Clinical Challenges That Arise from Success. 2007 Demystifying Medicine Series, NIH Graduate Partners Program, Bethesda, MD, January 7th, 2007.

52. African American Women and HIV; HIV and HPV Vaccines. Women & HIV International Clinical Conference, San Antonio, TX, March 4th-7th, 2007.
53. Keynote Speaker, Annual Savage Boyce Walton Dinner: HPV-Related Cancers in HIV-Infected and Immunocompromised Hosts and the Promise of HPV Vaccines. 2007 Annual Convention & Scientific Assembly, National Medical Association, Honolulu, HI, August 7th, 2007.
54. Program Faculty, The William McBride, M.D. Forum on Clinical Research: Non-Industry Opportunities to Conduct Clinical Research. 2007 Annual Convention & Scientific Assembly, National Medical Association, Honolulu, HI, August 8th, 2007.
55. The Current State of HIV Vaccine Development. 15th Annual Recent Advances in HIV Medicine, UT Southwestern Medical Center, Dallas, TX, October 27th, 2007.
56. HPV Vaccines: Immunization in HIV-Infected and Immunocompromised Hosts. Northern Virginia Local Performance Site of the Pennsylvania Mid-Atlantic AIDS Education and Training Center, Springfield, VA, February 29th, 2008.
57. Sex Differences in Immune Function and HIV Disease. Women & HIV International Clinical Conference, Dallas, TX, April 29th, 2008.
58. NIH Science in the Cinema Series: Discussion of the HBO Film Life Support and Review of Current Issues in HIV/AIDS Research and Treatment. American Film Institute, Silver Spring, MD, August 6th, 2008.
59. Adolescents and HIV: The Challenges of Generations X and Y. Northern Virginia Local Performance Site of the Pennsylvania Mid-Atlantic AIDS Education and Training Center, Springfield, VA, November 13th, 2008.
60. Epidemiologic Issues and Preventive Implications of HIV Co-Morbidities. 2008 AIDS Symposium, Medical University of South Carolina, Charleston, SC, November 21st, 2008.
61. Opening Plenary Keynote Speaker: Overcoming Scientific Challenges in HIV Prevention: Success, Setbacks and the Global Scorecard. 11th RCMi International Symposium on Health Disparities, University of Hawaii, Honolulu, HI, December 1st, 2008.
62. HIV Treatment: Clinical Challenges that Arise from Success. Special Interest Colloquia: AIDS Rethought: A Future Commensal?, 109th General Meeting, American Society for Microbiology, Philadelphia, PA, May 20th, 2009.
63. HIV/AIDS: Challenges in Preventive Strategies. 2009 AIDS Symposium, Medical University of South Carolina, Charleston, SC, November 20th, 2009.
64. HPV Vaccines: Immunization in HIV-Infected and Immunocompromised Hosts. 10th Annual Houston Premedical Academy Research Symposium, Baylor College of Medicine, Houston, TX, January 28th, 2010.